Skip to main content
COGT
NASDAQ Life Sciences

Fairmount Funds Sells $242.6M in Cogent Biosciences Stock After Preferred Conversion

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$38.5
Mkt Cap
$6.247B
52W Low
$3.72
52W High
$43.73
52W Position info
935% above low
Off High info
12% below high
Rel. Volume info
2.2× avg
Market data snapshot near publication time

COGT has more than doubled off its 52-week low of $3.72 on elevated volume (2.2× avg).

Summary

Fairmount Funds Management converted preferred stock and sold 7 million common shares of Cogent Biosciences for $242.6 million, reducing its ownership to 8.6%.


Key Events · Ownership and Investor Activity · COGT

  • Significant Stock Sale by Institutional Investor

    Fairmount Funds Management LLC sold 7,000,000 shares of common stock at $34.66 per share, totaling $242,620,000.

  • Preferred Stock Conversion

    Prior to the sale, Fairmount converted 28,000 shares of Series A Preferred Stock into 7,000,000 common shares without cash consideration.

  • Reduced Ownership Stake

    Following the transaction, Fairmount Funds Management LLC's beneficial ownership in Cogent Biosciences, Inc. decreased to 8.6% of the outstanding common stock.


Analysis · COGT · Life Sciences

Fairmount Funds Management, a significant institutional investor, converted a portion of its Series A Preferred Stock into common shares and subsequently sold a substantial block of 7 million common shares. This transaction, valued at over $242 million, represents a notable reduction in their stake in Cogent Biosciences, moving from a higher percentage to 8.6% of the outstanding common stock. While institutional investors often rebalance portfolios, a sale of this magnitude by a major holder can signal a shift in their investment thesis or a need for liquidity, potentially creating an overhang on the stock.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, COGT was trading at $38.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.2B. The 52-week trading range was $3.72 to $43.73. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

COGT - Latest Insights

COGT
Nov 05, 2026, 4:28 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $29.21
Real-time Price: $32.14 info
Change: +$2.93 (+10%) info
Market Cap: $5.505B info
COGT
Nov 05, 2026, 4:18 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $29.21
Real-time Price: $32.14 info
Change: +$2.93 (+10%) info
Market Cap: $5.505B info
COGT
Sep 15, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $33.50
Real-time Price: $32.14 info
Change: -$1.36 (-4%) info
Market Cap: $5.505B info
COGT
Aug 10, 2026, 4:11 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $41.53
Real-time Price: $32.14 info
Change: -$9.39 (-23%) info
Market Cap: $5.505B info
COGT
Aug 10, 2026, 8:06 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $40.55
Real-time Price: $32.14 info
Change: -$8.41 (-21%) info
Market Cap: $5.505B info